Clinical Trials Directory

Trials / Sponsors / Nanogen Pharmaceutical Biotechnology Joint Stock Company

Nanogen Pharmaceutical Biotechnology Joint Stock Company

Industry · 11 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingPharmacokinetics, Pharmacodynamics, and Safety of Nanokine Produced by Nanogen Pharmaceutical Joint Stock Comp
Natural Blood and Blood Product Toxicity
Phase 12025-06-01
CompletedPharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia i
Chronic Kidney Disease
Phase 12021-09-19
CompletedStudy to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19
SARS-CoV-2 Infection, COVID-19
Phase 32021-06-07
UnknownA Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers
COVID-19
Phase 1 / Phase 22020-12-10
CompletedA Study to Compare Efficacy and Safety of Nanogen's Darbepoetin Alfa With Aranesp® (Amgen) in the Treatment of
Anemia, Chronic Kidney Disease Requiring Chronic Dialysis
Phase 32019-08-08
CompletedClinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metas
Breast Cancer Metastatic, Breast Cancer Female, Breast Cancer Recurrent
Phase 12019-05-27
CompletedClinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cance
Breast Cancer Metastatic, Breast Cancer Recurrent, Breast Cancer Female
Phase 32018-02-02
CompletedNanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.
Breast Cancer Female
Phase 32016-10-06
CompletedNanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients
Breast Cancer
Phase 12016-05-25
CompletedThe Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunte
Hepatitis C
Phase 12013-12-01
CompletedStudy of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic
Chronic Hepatitis C
Phase 42011-03-01